Alogliptin for the treatment of type 2 diabetes

Drugs of Today

Volumn 47, Issue 2, 2011, Pages 99-107

  White Jr , John R ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; ATORVASTATIN; CIMETIDINE; CYCLOSPORIN; DIGOXIN; DIHYDROPYRIMIDINASE; DILTIAZEM; ETHINYLESTRADIOL; FLUCONAZOLE; GEMFIBROZIL; GLIBENCLAMIDE; GLIPIZIDE PLUS METFORMIN; GLUCAGON LIKE PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; KETOCONAZOLE; LINAGLIPTIN; METFORMIN; NORETHISTERONE; PIOGLITAZONE; RIFAMPICIN; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; WARFARIN;

AREA UNDER THE CURVE; BLOOD CHEMISTRY; BLOOD LEVEL; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; DIABETIC PATIENT; DIZZINESS; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FOOD; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HEMATOLOGY; HUMAN; HYPOGLYCEMIA; INFECTION RISK; INSULIN TREATMENT; KIDNEY FAILURE; LIPID BLOOD LEVEL; LIVER DISEASE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; URINALYSIS; VITAL SIGN;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG APPROVAL; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; HUMANS; HYPOGLYCEMIC AGENTS; PIPERIDINES; TREATMENT OUTCOME; URACIL;

EID: 79955901224     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.2.1583163     Document Type: Review

References (34)

1. Gerich, J. DPP-4 inhibitors: what may be the clinical differentiators? Diabetes Res Clin Pract 2010, 90(2): 131-40.
2. Clinical.Trials.gov Web site, http://clinicaltrials.gov/ct2/results?term= dutogliptin. Accessed February 7, 2011.
3. PPD confirms Takeda receives NDA approval of Nesina® (alogliptin) from Japanese Ministry of Health, Labour and Welfare [news release]. PPD, Inc., April 26, 2010. http://investor.ppdi.com/releasedetail.cfm?ReleaseID=463452. Accessed February 4, 2011.
4. Deacon, C.F. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. Curr Opin Investig Drugs 2008, 9(4): 402-13.
5. Ghatak, S.B., Patel, D.S., Shanker, N., Srivstava, A., Deshpande, S.S., Panchal, S.J. Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus. Curr Diabetes Rev 2010, 6(6): 410-21.
6. Drucker, D.J., Nauck, M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368(9548): 1696-705.
7. Gonzalez, C., Beruto, V., Keller, G., Santoro, S., Di Girolamo, G. Investigational treatments for type 2 diabetes mellitus: exenatide and liraglutide. Expert Opin Investig Drugs 2006, 15(8): 887-95.
8. Sudre, B., Broqua, P., White, R.B. et al. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats. Diabetes 2002, 51(5): 1461-9.
9. Pospisilik, J.A., Stafford, S.G., Demuth, H.U., McIntosh, C.H., Pederson, R.A. Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. Diabetes 2002, 51(9): 2677-83.
10. White, J. The role of DPP-IV inhibitors in type 2 diabetes: Saxagliptin, an efficacious and well-tolerated treatment option. Advance PA 2010, 18(5): 24-31.
11. Zettl, H., Schubert-Zsilavecz, M., Steinhilber, D. Medicinal chemistry of incretin mimetics and DPP-4 inhibitors. ChemMedChem 2010, 5(2): 179-85.
12. Thornberry, N.A., Weber, A.E. Discovery of JANUVIA (sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr Top Med Chem 2007, 7(6): 557-68.
13. Deng, J., Peng, L., Zhang, G. et al. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes. Eur J Med Chem 2010, 46(1): 71-6.
14. Scheen, A.J. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010, 12(8): 648-58.
15. Scheen, A.J. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010, 49(9): 573-88.
16. Christopher, R., Covington, P., Davenport, M., Fleck, P., Mekki, Q.A., Wann, E.R., Karim, A. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther 2008, 30(3): 513-27.
17. Karim, A., Covington, P., Christopher, R. et al. Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects. Int J Clin Pharmacol Ther 2010, 48(1): 46-58.
18. Covington, P., Christopher, R., Davenport, M., Fleck, P., Mekki, Q.A., Wann, E.R., Karim, A. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther 2008, 30(3): 499-512.
19. Karim, A., Fleck, P., Hetman, L. Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment. Diabetes [68th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 6-10, San Francisco) 2008] 2008, 57(Suppl. 1): Abst 538-P.
20. Karim, A., Fleck, P., Dorsey, D., Zhang, W., Mekki, Q., Preston, R.A. Single-dose pharmacokinetics of alogliptin benzoate (SYR-322), a highly selective dipeptidyl peptidase-4 inhibitor, in subjects with moderate hepatic impairment. J Clin Pharmacol [36th Annu Meet Am Coll Clin Pharmacol (ACCP) (September 9-11, San Francisco) 2007] 2007, 47(9): Abst 107.
21. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/results?term= alogliptin&phase=12&pg=1&show-flds=Y. Accessed February 7, 2011.
22. Nauck, M.A., Ellis, G.C., Fleck, P.R., Wilson, C.A., Mekki, Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009, 63(1): 46-55.
23. Pratley, R.E., Reusch, J.E., Fleck, P.R., Wilson, C.A., Mekki, Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2009, 25(10): 2361-71.
24. Rosenstock, J., Inzucchi, S.E., Seufert, J., Fleck, P.R., Wilson, C.A., Mekki, Q. Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes. Diabetes Care 2010, 33(11): 2406-8.
25. Pratley, R.E., Kipnes, M.S., Fleck, P.R., Wilson, C., Mekki, Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009, 11(2): 167-76.
26. Rosenstock, J., Rendell, M.S., Gross, J.L., Fleck, P.R., Wilson, C.A., Mekki, Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab 2009, 11(12): 1145-52.
27. Pratley, R.E., McCall, T., Fleck, P.R., Wilson, C.A., Mekki, Q. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc 2009, 57(11): 2011-9.
28. Takeda submits New Drug Application for alogliptin (SYR-322) in the U.S. [news release]. Takeda Pharmaceutical Company Limited, January 4, 2008. http://www.takeda.com/press/article-28864.html. Accessed February 7, 2011.
29. Takeda receives FDA complete response letter for alogliptin, an investigational treatment for type 2 diabetes [news release]. Takeda Pharmaceutical Company Limited, June 26, 2009. http://www.takeda.com/press/ article-34760.html. Accessed February 7, 2011.
30. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry. Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. December 2008. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed February 7, 2011.
31. Cardiovascular outcomes study of alogliptin in subjects with type 2 diabetes and acute coronary syndrome (EXAMINE) (NCT00968708). ClinicalTrials.gov Web site, Accessed February 7, 2011.
32. Efficacy and safety of alogliptin plus metformin in subjects with type 2 diabetes (AM7D) (NCT01023581). ClinicalTrials. gov Web site, Accessed February 10, 2011.
33. Efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in subjects with type 2 diabetes mellitus (ENDURE) (NCT00856284). ClinicalTrials.gov Web site, Accessed February 10, 2011.
34. Richter, B., Bandeira-Echtler, E., Bergerhoff, K., Lerch, C.L. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008(2): CD006739.